Safety of using the 300 IR tablet containing house dust mite allergens for sublingual immunotherapy Review: Worm M, Demoly P, Okamoto Y et al. Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data.
Article Sidebar
Main Article Content
Abstract
A meta-analysis assessing the safety of 300 IR SLIT-HDM tablets demonstrated good tolerability in adults, adolescents, and children with allergic rhinitis, with or without concomitant asthma. The analysis included eight randomized clinical trials and post-marketing pharmacovigilance data covering over 235,000 patients. The most frequently reported adverse events were mild to moderate local reactions, primarily occurring in the first weeks of therapy. Severe reactions were rare and effectively managed with symptomatic treatment. The study results confirm that 300 IR HDM SLIT tablet has a favorable safety profile consistent with previous scientific observations and international recommendations.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Creticos PS, Gunaydin FE, Nolte H et al. Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma. J Allergy Clin Immunol Pract. 2024; 12(6): 1415-27. http://doi.org/10.1016/j.jaip.2024.04.034.
3.Li X, Shang J, Liu J et al. A meta-analysis investigating the efficacy and safety of allergen-specific immunotherapy in the management of respiratory allergies. J Asthma. 2024; 61(10): 1337-46. http://doi.org/10.1080/02770903.2024.2349604.
4. Bousquet J, Pfaar O, Agache I et al. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. Clin Transl Allergy. 2021; 11(4): e12014. http://doi.org/10.1002/clt2.12014.
5. Okamoto Y, Kato M, Ishii K et al. Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan. Immunotherapy. 2023; 15(16): 1401-14. http://doi.org/10.2217/imt-2023-0100.
6. Turner PJ, Ansotegui IJ, Campbell DE et al.; WAO Anaphylaxis Committee and WAO Allergen Immunotherapy Committee. Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee. World Allergy Organ J. 2024; 17(3): 100876. http://doi.org/10.1016/j.waojou.2024.100876.
7. Horn A, Bernstein DI, Okubo K et al. House dust mite sublingual immunotherapy tablet safety in adolescents with allergic rhinoconjunctivitis: Worldwide clinical trial results. Ann Allergy Asthma Immunol. 2023; 130(6): 797-804.e2. http://doi.org/10.1016/j.anai.2023.03.006.
8. Demoly P, Corren J, Creticos P et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo- controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2021; 147(3): 1020-30.e10. http://doi.org/10.1016/j.jaci.2020.07.036.
9. Worm M, Demoly P, Okamoto Y et al. Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data. World Allergy Organ J. 2024; 17(7): 100924. http://doi.org/10.1016/j.waojou.2024.100924.